In Reply We thank Cui and Liu as well as Dravland for their thoughtful comments about our work.1 Cui and Liu point out that we did not include a Chinese study by Zheng et al.2 This omission is unfortunate because it would have partly balanced the overrepresentation of North American data. The study is interesting because although in a cohort of 153 children aged 6 to 12 years the chosen dose range for titration of osmotic-release oral system methylphenidate (OROS-MPH) was 18 to 54 mg/d, after 12 weeks, the mean titrated dose was only 22.8 mg/d, and there were no children receiving 54 mg. Whether this reflects differences in cohort selection, differences in ADHD expression, or differences in treatment is unclear. Another important study that we did not include was the Multimodal Treatment of ADHD (MTA) Study.3 This was because 10% of the included children were titrated onto receiving dexamphetamine because they had significant residual symptoms or adverse effects while receiving methylphenidate and were considered nonresponders.3
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Poulton AS, Eslick GD. Effective Stimulant Dosing in Attention-Deficit/Hyperactivity Disorder—Reply. JAMA Pediatr. 2019;173(12):1211–1212. doi:10.1001/jamapediatrics.2019.3820
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: